- Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R.
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., in press (2019) - Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K.
- A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019) - Matsumura, S., Minamisawa, T., Suga, K., Kishita, H., Akagi, T., Ichiki, T., Ichikawa, Y. and Shiba, K.
- Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
J. Extracell. Vesicles, 8, (2019) - Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H.
- Clinical utility of circulating tumor DNA for colorectal cancer.
Cancer Sci., in press (2019) - Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T. and Zembutsu, H.
- Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Cancer Med., 8, 408-417 (2019)
more
